Literature DB >> 15857842

Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.

H Shimada, H Shima, N Shimasaki, H Yoshihara, T Mori, T Takahashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15857842     DOI： 10.1093/annonc/mdi233

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.

Authors:  Charlotte M Niemeyer; Mignon L Loh; Annamaria Cseh; Todd Cooper; Christopher C Dvorak; Rebecca Chan; Blanca Xicoy; Ulrich Germing; Seiji Kojima; Atsushi Manabe; Michael Dworzak; Barbara De Moerloose; Jan Starý; Owen P Smith; Riccardo Masetti; Albert Catala; Eva Bergstraesser; Marek Ussowicz; Oskana Fabri; André Baruchel; Hélène Cavé; Michel Zwaan; Franco Locatelli; Henrik Hasle; Marry M van den Heuvel-Eibrink; Christian Flotho; Ayami Yoshimi
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

Review 2.  Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.

Authors:  Ayami Yoshimi; Seiji Kojima; Naoto Hirano
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

3.  Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells.

Authors:  Emanuela Chiarella; Bruna Codispoti; Annamaria Aloisio; Emanuela G Cosentino; Stefania Scicchitano; Ylenia Montalcini; Daniela Lico; Giovanni Morrone; Maria Mesuraca; Heather M Bond
Journal:  Heliyon       Date:  2020-06-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.